The U.S. Food and Drug Administration gave full approval Monday to the Pfizer COVID-19 vaccine, a major step that will likely have significant implications for vaccination mandates nationwide. The Moderna and Johnson & Johnson vaccines have not yet received full FDA authorization.
The Pfizer vaccine previously received FDA authorization, which allowed its emergency use but did not give the full approval. Pfizer is the first company to receive full approval in the U.S.
Read More
The Biden administration announced Wednesday that federal health experts now recommend vaccinated Americans receive a COVID booster shot.
The boosters will be widely distributed to the public after research indicated that the vaccine’s effectiveness declines over time.
Read More
It was always going to be Herculean to inoculate, with an untried vaccine, a multi-ethnic nation of 330 million, across a vast continent—in an era when the media routinely warps the daily news.
Some minorities understandably harbored distrust of prior government vaccination programs.
Read More
Joe Biden is planning an effort to distribute doses of the Johnson & Johnson vaccine to illegal aliens pouring into the United States across the southern border, as reported by Breitbart.
The report first came from the Washington Post, after several officials with the Department of Homeland Security (DHS) spoke under condition of anonymity. According to the officials, federal authorities will soon begin administering the single-shot vaccine to illegals currently held in U.S. custody along the southern border with Mexico. DHS plans to get illegals vaccinated as soon as possible upon their entry into the country, to be done even before they are fully processed.
Read More
For the first time in months, not one state reported a dramatic weekly increase in coronavirus cases.
While average daily cases fell by less than 10% in 11 states, 37 states saw cases fall by over 10% and just two states had cases marginally increase, according to data from Johns Hopkins University. The United States also averaged fewer than 40,000 daily cases last week, a 21% drop from the week prior and the lowest total since September.
Death and hospitalization rates have also plummeted nationwide. The U.S. has averaged 600 deaths per day, the lowest point in approximately 10 months. If the number continues to fall the nation could soon hit its lowest point of the entire pandemic, according to the Associated Press.
Read More
Pfizer’s coronavirus vaccine was over 94% effective in preventing asymptomatic cases of COVID-19, according to real-world Israeli data released late Thursday.
The latest analysis suggests that Pfizer’s vaccine could overwhelmingly halt asymptomatic spread — a main driver of infections since asymptomatic people are often unaware they have the virus. The data also showed that the vaccine was 97% effective in preventing symptomatic cases, hospitalizations and deaths, slightly higher than the 95% effectiveness found in its clinical trials.
Read More
Pfizer said Wednesday that real-world data suggests its coronavirus vaccine is 94% effective in halting asymptomatic infections and effective against a highly transmissible variant first discovered in the United Kingdom.
Israeli analysis of vaccine distribution shows the vaccine being over 97% effective in preventing symptomatic cases and death, higher than the 90% efficiency that was reported in the vaccine’s Phase III trials, Pfizer said in a press release Thursday. Over 80% of the tested specimens were against the UK variant known as B.1.1.7.
Read More
Pfizer’s coronavirus vaccine was able to neutralize the highly transmissible Brazilian virus variant, a new lab study showed.
The effectiveness of the vaccine against the variant was “roughly equivalent” to the original strain, researchers told the New England Journal of Medicine. Its ability to combat the variant, known as P.1, is especially encouraging in Brazil, where it has spread throughout the country.
Read More
Recent studies indicate that the Pfizer and Moderna coronavirus vaccines may have reduced protection against the South African coronavirus strain, according to reports in the New England Journal of Medicine, raising concerns that they could be less effective against future mutations.
Though both vaccines appeared to generate enough antibodies to neutralize the mutant strain, they both produced fewer antibodies when compared to the original virus. But experts warned that it was unclear just how much protection was needed to neutralize the variant, which scientists believe is more contagious than the original strain.
Read More